{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:59:10Z","timestamp":1783645150462,"version":"3.55.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To discuss changes in epidemiology, recent advances in understanding of the pathogenesis and management of selected extraarticular manifestations of rheumatoid arthritis (ExRA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The incidence of ExRA overall and subcutaneous rheumatoid nodules in particular is declining after 2000. These trends reflect improved RA disease activity with early effective immunosuppressive treatments; changing environmental risk factors can be contributing. ExRA continues to carry a two-fold increased mortality risk. RA-associated interstitial lung disease (RA-ILD) is a major contributor to mortality, with no decline in incidence and scant therapeutic options. Individualized risk stratification for RA-ILD based on patient-level risk factors and biomarker profile is evolving with MUC5B as a major genetic risk factor. Clinical trials are underway to evaluate the benefits of novel antifibrotic therapies and targeted therapies for RA-ILD. The risk of cardiovascular disease in RA is generally amendable to treatment with disease-modifying antirheumatic drugs, although cardiovascular risk associated with JAK inhibition is not fully understood.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Despite reduction in incidence of ExRA overall, the incidence of RA-ILD shows no significant decline and remains a major therapeutic challenge. The use of novel antifibrotics and immunosuppressive drugs shows promise in slowing the progression of RA-ILD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001007","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T12:00:09Z","timestamp":1709035209000},"page":"203-208","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis"],"prefix":"10.1097","volume":"36","author":[{"given":"Elena","family":"Myasoedova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Matteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N Engl J Med"},{"key":"R2-20250526","article-title":"Decline in incidence of extraarticular manifestations of rheumatoid arthritis: a population-based cohort study","author":"Kimbrough","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3899\/jrheum.161103","article-title":"Severe extraarticular manifestations in a community-based cohort of patients with rheumatoid arthritis: risk factors and incidence in relation to treatment with tumor necrosis factor inhibitors","volume":"44","author":"Theander","year":"2017","journal-title":"J Rheumatol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s42358-023-00318-y","article-title":"Extra-articular manifestations of rheumatoid arthritis remain a major challenge: data from a large, multicentric cohort","volume":"63","author":"Bonfiglioli","year":"2023","journal-title":"Adv Rheumatol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2017-212426","article-title":"Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register","volume":"77","author":"Gwinnutt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1136\/annrheumdis-2020-217609","article-title":"Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population","volume":"81","author":"Matthijssen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/annrheumdis-2019-216694","article-title":"Results from a population-based incidence study, 1985\u20132014","volume":"79","author":"Myasoedova","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"152187","DOI":"10.1016\/j.semarthrit.2023.152187","article-title":"Survival of adults with rheumatoid arthritis associated interstitial lung disease - a systematic review and meta-analysis","volume":"60","author":"Farquhar","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/acr.24856","article-title":"Incidence, risk factors, and mortality of clinical and subclinical rheumatoid arthritis-associated interstitial lung disease: a population-based cohort","volume":"74","author":"Samhouri","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/acr.25053","article-title":"A narrowing mortality gap: temporal trends of cause-specific mortality in a national matched cohort study in US veterans with rheumatoid arthritis","volume":"75","author":"Johnson","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"e003059","DOI":"10.1136\/rmdopen-2023-003059","article-title":"Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review","volume":"9","author":"Matteson","year":"2023","journal-title":"RMD Open"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/cells12182235","article-title":"Molecular factors in PAD2 (PADI2) and PAD4 (PADI4) are associated with interstitial lung disease susceptibility in rheumatoid arthritis patients","volume":"12","author":"Nava-Quiroz","year":"2023","journal-title":"Cells"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/rheumatology\/keac667","article-title":"Antiprotein arginine deiminase antibodies are distinctly associated with joint and lung involvement in rheumatoid arthritis","volume":"62","author":"Palterer","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1136\/annrheumdis-2021-220698","article-title":"Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers","volume":"80","author":"Palomaki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/1756-185X.14351","article-title":"Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: a single-center retrospective study from China","volume":"25","author":"Liu","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/art.42640","article-title":"Identification, monitoring, and management of rheumatoid arthritis\u2013associated interstitial lung disease","volume":"75","author":"Koduri","year":"2023","journal-title":"Arthritis Rheum"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"e22336","DOI":"10.1096\/fj.202101436R","article-title":"Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis","volume":"36","author":"Wang","year":"2022","journal-title":"FASEB J"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.chest.2022.01.007","article-title":"Acute respiratory deterioration in rheumatoid arthritis-associated interstitial lung disease: a single-center study","volume":"162","author":"Kwon","year":"2022","journal-title":"Chest"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3390\/biomedicines10071480","article-title":"Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis-associated interstitial lung disease","volume":"10","author":"Mena-Vazquez","year":"2022","journal-title":"Biomedicines"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","article-title":"Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory","volume":"163","author":"Matson","year":"2023","journal-title":"Chest"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An Official American Thoracic Society Clinical Practice Guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"R24-20250526","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221074457","article-title":"The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease","volume":"14","author":"Liang","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-023-06623-7","article-title":"Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial","volume":"42","author":"Matteson","year":"2023","journal-title":"Clin Rheumatol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"R1386","DOI":"10.1186\/ar1837","article-title":"The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis","volume":"7","author":"Turesson","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3324\/haematol.2017.175729","article-title":"Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia","volume":"103","author":"Savola","year":"2018","journal-title":"Haematologica"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.seminhematol.2022.07.004","article-title":"The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome","volume":"59","author":"Savola","year":"2022","journal-title":"Semin Hematol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5114\/reum\/167472","article-title":"Biological treatment in Felty's syndrome with profound neutropenia","volume":"61","author":"Proc","year":"2023","journal-title":"Reumatologia"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1002\/art.22057","article-title":"Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis","volume":"54","author":"Turesson","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/rheumatology\/keq135","article-title":"Changing trends in serious extra-articular manifestations of rheumatoid arthritis among United State veterans over 20\u200ayears","volume":"49","author":"Bartels","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/ket326","article-title":"Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy","volume":"53","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3899\/jrheum.101133","article-title":"Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995\u20132007 versus 1985\u20131994: a population-based study","volume":"38","author":"Myasoedova","year":"2011","journal-title":"J Rheumatol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.semarthrit.2020.01.004","article-title":"Prevalence and clinical significance of extra-articular manifestations at diagnosis in the ESPOIR cohort with recent-onset arthritis","volume":"50","author":"Guellec","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1038\/s41467-023-41876-5","article-title":"ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon","volume":"14","author":"Hartmann","year":"2023","journal-title":"Nat Commun"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/annrheumdis-2014-206411","article-title":"The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease","volume":"75","author":"Myasoedova","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/ard.2006.052506","article-title":"Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis","volume":"66","author":"Turesson","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"1099861","DOI":"10.3389\/fcvm.2023.1099861","article-title":"Relationship between rheumatoid arthritis and cardiovascular comorbidity, causation or co-occurrence: a Mendelian randomization study","volume":"10","author":"Wang","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.amjmed.2013.02.016","article-title":"Cardiovascular risk in rheumatoid arthritis: comparing TNF-alpha blockade with nonbiologic DMARDs","volume":"126","author":"Solomon","year":"2013","journal-title":"Am J Med"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"e018290","DOI":"10.1161\/JAHA.120.018290","article-title":"Patients with rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs at a higher risk of acute coronary syndrome","volume":"10","author":"Hsu","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"e0220178","DOI":"10.1371\/journal.pone.0220178","article-title":"Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis","volume":"14","author":"Castagne","year":"2019","journal-title":"PLoS One"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/ard-2022-223302","article-title":"Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis","volume":"82","author":"Solomon","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/rheumatology\/kead198","article-title":"Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry","volume":"63","author":"Mok","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"e003489","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"key":"R49-20250526","article-title":"Changes in renal function and morphological variations of kidney diseases in rheumatoid arthritis patients","author":"Tang","year":"2022","journal-title":"Asian J Urol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"1116489","DOI":"10.3389\/fmed.2023.1116489","article-title":"Rheumatoid arthritis and the risk of end-stage renal disease: a nationwide, population-based study","volume":"10","author":"Suh","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ckj\/sfac036","article-title":"Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying antirheumatic drugs","volume":"15","author":"Hanaoka","year":"2022","journal-title":"Clin Kidney J"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:18:03Z","timestamp":1748294283000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001007","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]}}}